Literature DB >> 27021004

Inhibition of phospho-MurNAc-pentapeptide translocase (MraY) by nucleoside natural product antibiotics, bacteriophage ϕX174 lysis protein E, and cationic antibacterial peptides.

Timothy D H Bugg1, Maria T Rodolis2, Agnes Mihalyi2, Shirin Jamshidi2.   

Abstract

This review covers recent developments in the inhibition of translocase MraY and related phospho-GlcNAc transferases WecA and TagO, and insight into the inhibition and catalytic mechanism of this class of integral membrane proteins from the structure of Aquifex aeolicus MraY. Recent studies have also identified a protein-protein interaction site in Escherichia coli MraY, that is targeted by bacteriophage ϕX174 lysis protein E, and also by cationic antimicrobial peptides containing Arg-Trp close to their N- or C-termini. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacteriophage lysis protein E; Cationic antimicrobial peptides; Enzyme inhibition; Nucleoside antibiotics; Peptidoglycan biosynthesis; Translocase MraY

Mesh：

Substances：

Year:  2016        PMID： 27021004     DOI： 10.1016/j.bmc.2016.03.018

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  10 in total

1.  Insights into the Target Interaction of Naturally Occurring Muraymycin Nucleoside Antibiotics.

Authors:  Stefan Koppermann; Zheng Cui; Patrick D Fischer; Xiachang Wang; Jannine Ludwig; Jon S Thorson; Steven G Van Lanen; Christian Ducho
Journal:  ChemMedChem       Date:  2018-03-23       Impact factor: 3.466

2.  Targeting the gram-negative bacteria peptidoglycan synthase MraY as a new approach for monoclonal antibody anti-bacterial activity.

Authors:  Jun Cao; Fei Yi; Qiufeng Tian; Guanghui Dang; Wei Si; Siguo Liu; Shenye Yu
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

Review 3.  Anti-bacterial monoclonal antibodies: next generation therapy against superbugs.

Authors:  Hui Wang; Daijie Chen; Huili Lu
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-01       Impact factor: 4.813

Review 4.  GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review.

Authors:  Roberto De Masi; Stefania Orlando
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

5.  Analyzing native membrane protein assembly in nanodiscs by combined non-covalent mass spectrometry and synthetic biology.

Authors:  Erik Henrich; Oliver Peetz; Christopher Hein; Aisha Laguerre; Beate Hoffmann; Jan Hoffmann; Volker Dötsch; Frank Bernhard; Nina Morgner
Journal:  Elife       Date:  2017-01-09       Impact factor: 8.140

6.  Pac13 is a Small, Monomeric Dehydratase that Mediates the Formation of the 3'-Deoxy Nucleoside of Pacidamycins.

Authors:  Freideriki Michailidou; Chun-Wa Chung; Murray J B Brown; Andrew F Bent; James H Naismith; William J Leavens; Sean M Lynn; Sunil V Sharma; Rebecca J M Goss
Journal:  Angew Chem Int Ed Engl       Date:  2017-08-30       Impact factor: 15.336

7.  Analogues of Muraymycin Nucleoside Antibiotics with Epimeric Uridine-Derived Core Structures.

Authors:  Anatol P Spork; Stefan Koppermann; Stephanie Schier Née Wohnig; Ruth Linder; Christian Ducho
Journal:  Molecules       Date:  2018-11-03       Impact factor: 4.411

Review 8.  Peptidoglycan pathways: there are still more!

Authors:  Ahmed M Helal; Ahmed M Sayed; Mariam Omara; Mohamed M Elsebaei; Abdelrahman S Mayhoub
Journal:  RSC Adv       Date:  2019-09-09       Impact factor: 4.036

9.  Membrane association of monotopic phosphoglycosyl transferase underpins function.

Authors:  Leah C Ray; Debasis Das; Sonya Entova; Vinita Lukose; Andrew J Lynch; Barbara Imperiali; Karen N Allen
Journal:  Nat Chem Biol       Date:  2018-05-16       Impact factor: 15.040

10.  Muraymycin Nucleoside Antibiotics: Structure-Activity Relationship for Variations in the Nucleoside Unit.

Authors:  Anna Heib; Giuliana Niro; Stefanie C Weck; Stefan Koppermann; Christian Ducho
Journal:  Molecules       Date:  2019-12-19       Impact factor: 4.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.